CAS 274901-16-5 Puritas ≥99.0% (HPLC) API
| Synonyma | LAF-237 |
| CAS Number | 274901-16-5 |
| CATTUS Number | RF-API30 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C17H25N3O2 |
| M. Pondus | 303.4 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Crystallina pulveris alba |
| Lepidium sativum | IR, HPLC: oportet quod Reference Standard |
| Imprimis Rotatione Optica | -82.0° to -92.0° |
| Liquescens punctum | 148.0~152.0℃ |
| Damnum in Siccatio | ≤0.50% |
| Residere in Ignition | ≤0.10% |
| Metalla gravis | ≤20ppm |
| Sulphate | ≤0.04% |
| Chloride | ≤0.05% |
| Chiral immunditia | R-Isomer immunditiam ≤0.50% |
| RELICTUM Solvents | |
| Acetonitrile | ≤410ppm |
| Dichloromethane | ≤600ppm |
| Isopropyl Sin | ≤5000ppm |
| Related immunditias | per HPLC |
| immunditiam A | ≤0.15% |
| impudicitia B | ≤0.15% |
| immunditia C | ≤0.20% |
| Alia immunitas | ≤0.10% |
| Totalis immunditias | ≤1.00% |
| Puritas / Analysis Methodus | ≥99.0% (HPLC) |
| Test Standard | Enterprise Standard |
| Consuetudinem | API, Type 2 Diabetes Mellitus (T2DM) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica et supplementum API (CAS: 274901-16-5) magna qualitate.API (CAS: 274901-16-5)est agentis oralis anti-hyperglycemici (medicamentum anti-diabeticum) novi dipeptidyli peptidasi-4 (DPP-4) inhibitoris medicamentorum ordinis.A Novartis (Novartis) pharmaceutica Co, Ltd, alia oralis administrata inhibitor of Dipeptidyl peptidasi-IV est evoluta.Anno 2008 venalicium in Unione Europaea probatum est pro curatione speciei 2 diabete.API (CAS: 274901-16-5) vetat inactionem GLP-I et GIP ab DPP-4, permittens GLP-1 et GIP potentiam insulin in cellulis insulinis potentiare et glucagonum reprimere per alpha cellulis emissio insulae de Langerhans in pancreate.API (CAS: 274901-16-5) ostensum est reducere hyperglycemiam in specie 2 diabete melliti.
